Getting GLP-1 Coverage: The Working Appeal Playbook for Wegovy, Zepbound, and Ozempic Denials in 2026

The most-searched consumer health-insurance denial pattern of 2026, on every working dataset I have access to, involves a GLP-1 receptor agonist. The class includes semaglutide, marketed as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, marketed as Mounjaro and Zepbound by Eli Lilly. List prices sit in the $970 to $1,350 per month range, depending on brand and dose, with KFF tracking annual payer exposure that runs into the billions for a single carrier. The denial letter that arrives at the kitchen counter does not look like a billing dispute. It looks like a medical-policy decision. It is almost always procedural.

This is a working guide for the patient who already has a denial letter for Ozempic, Wegovy, Mounjaro, or Zepbound and is trying to figure out what kind of denial it actually is, whether the appeal is worth filing, and what the appeal letter has to contain to get the carrier's pharmacy reviewer to take a second look. Apellica prepares GLP-1 appeals for a living, so my hand is on the scale. I have tried to flag where.

A note on sources. Every regulatory citation here points to eCFR, to the Medicare statute at 42 USC 1395w-102, or to FDA labeling posted at accessdata.fda.gov. The trial citation for the cardiovascular indication is the SELECT trial in the New England Journal of Medicine, December 2023. The payer-side coverage data comes from KFF's tracking and from carrier formulary notices published in 2024 and 2025.

The four denial archetypes

Almost every GLP-1 denial under appeal in 2026 falls into one of four patterns. The four patterns require different rebuttals, and the appeal that treats one archetype as if it were another is the most common reason a first-level appeal comes back upheld.

The first archetype is the not-medically-necessary denial for weight management. The letter cites the carrier's pharmacy policy and states the medication is not covered for the treatment of obesity, often regardless of BMI or comorbidity. The language patients see in this lane is some variation of "not medically necessary for the treatment of obesity under your pharmacy benefit." The archetype is most common in ERISA self-funded plans that have excluded the anti-obesity drug class from the pharmacy benefit entirely. It is also the operative pattern in Medicare Part D, where the statutory exclusion at 42 USC 1395w-102(e)(2)(A) has historically blocked coverage of any drug used for "anorexia, weight loss, or weight gain."

The second archetype is the step-therapy denial. The letter accepts that the patient is a candidate for pharmacotherapy but requires documented prior trial and failure of one or more preferred agents, typically phentermine, orlistat, naltrexone-bupropion, or in some plans a less-expensive GLP-1 such as liraglutide. The framework is governed for Medicare Advantage by 42 CFR 422.136 and for commercial plans by the carrier's pharmacy policy and the applicable state step-therapy override law. Step therapy is the most common denial pattern for patients who switched plans mid-treatment.

The third archetype is the experimental-or-investigational denial. The letter argues that GLP-1 therapy is investigational for obesity in adults without specific comorbidities. The pattern is procedurally weak in 2026 because Wegovy was FDA-approved for chronic weight management in adults with obesity or with overweight plus at least one weight-related comorbid condition in June 2021, and Zepbound was approved for the same indication in November 2023. An experimental denial against an FDA-approved indication is appealable on its face under 21 CFR Part 201 and the carrier's own definition of the term, which almost always exempts FDA-approved uses.

The fourth archetype is the prescriber-credentialing denial. The letter denies because the prescribing physician is not credentialed in endocrinology, bariatric medicine, or whatever specialty the pharmacy policy specifies. The rebuttal is a policy-language argument backed by the carrier's own network adequacy obligations and, in many states, by state medical-practice scope law.

A single denial sometimes stacks more than one archetype. The most common stack is not-medically-necessary plus step-therapy plus BMI threshold, all in the same letter, and the appeal has to address each one to clear the route.

The five-regime coverage landscape

GLP-1 coverage in 2026 is not one market. It is five markets, each running on a different rule set, and the first task of any GLP-1 appeal is identifying which regime the patient sits in.

ACA Marketplace plans vary state by state. The Essential Health Benefits framework at 45 CFR 156.110 requires coverage of prescription drugs as one of the ten EHB categories, but each state's benchmark plan defines the specific formulary obligation. Some include anti-obesity medications. Most do not. The diabetes indication is widely covered.

Commercial fully insured employer plans run on the carrier's commercial formulary, which is typically more generous than the Marketplace product but has been tightening rapidly. Multiple carriers narrowed GLP-1 obesity coverage in 2024 and 2025 with BMI thresholds, prior-authorization documentation requirements, and step-therapy gates. CVS Caremark removed Zepbound from its preferred template formulary effective July 1, 2025, routing patients to Wegovy as the preferred alternative under a Novo Nordisk rebate agreement. Express Scripts and OptumRx maintained both on their preferred lists with prior-authorization gating.

Medicare Part D is the most restrictive lane. The Medicare Modernization Act of 2003, codified at 42 USC 1395w-102(e)(2)(A), excludes drugs used for "anorexia, weight loss, or weight gain" from Part D coverage. The exclusion applies to Wegovy and Zepbound when prescribed for obesity. It does not apply to the same molecule prescribed for an indication that is not weight loss. Semaglutide as Ozempic for type 2 diabetes is covered. Semaglutide as Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, the indication FDA added in March 2024 following the SELECT trial, is covered under a CMS clarification issued the same month because the labeled indication is cardiovascular event reduction rather than weight loss.

Medicaid coverage is set state by state. As of mid-2026, a minority of state Medicaid programs cover GLP-1 medications for the obesity indication, while a majority cover them only for the diabetes indication. The list moves quarterly, with several states running pilots tied to projected federal pricing changes under the Inflation Reduction Act negotiation framework. ERISA self-funded employer plans are the most restrictive category in the commercial market. Because the plan sponsor designs the benefit, and a self-funded plan is not subject to state-level mandates or to the ACA Essential Health Benefit framework, the plan can exclude anti-obesity medications outright. A 2025 Mercer National Survey of Employer-Sponsored Health Plans found a meaningful share of large self-funded plans had either excluded GLP-1 for obesity entirely or imposed BMI and comorbidity gates beyond the carrier's standard pharmacy policy.

BMI thresholds and the comorbidity question

Almost every carrier policy that covers GLP-1 for obesity uses one of two BMI thresholds. The first is BMI of 30 or greater, which corresponds to the FDA labeling for Wegovy and Zepbound in adults with obesity. The second is BMI of 27 or greater with at least one weight-related comorbid condition. Most policies count type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease. Some include prediabetes, non-alcoholic fatty liver disease, polycystic ovary syndrome, and osteoarthritis. Some do not.

The documentation requirement matters more than the threshold itself. A patient whose chart shows a BMI of 32 and an ICD-10-coded diagnosis of hypertension meets almost every commercial policy. A patient whose chart shows the same BMI but no ICD-10-coded diagnosis, even while actively taking lisinopril, will often be denied for missing documentation. The fix sits in the chart, not in the appeal letter. The step-therapy documentation requirement runs on the same logic. "The patient tried phentermine years ago" is rarely sufficient. The carrier wants dates, doses, duration of therapy, and the reason discontinued, drawn from the medical record at specific source-page citations.

The cardiovascular indication path

The SELECT trial, published in the New England Journal of Medicine in December 2023, randomized 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo and followed them for a mean of roughly 40 months. The primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was reduced by approximately 20 percent in the semaglutide arm. The trial led FDA to approve a new Wegovy indication in March 2024 for the reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

The cardiovascular indication is the single most useful procedural lever in the GLP-1 appeal toolkit. It is an FDA-labeled indication, which defeats the experimental-or-investigational denial on its face. It is not a weight-loss indication, which defeats the Medicare Part D statutory exclusion when the prescription is coded correctly at the prior-authorization stage. And it is supported by a Level 1 randomized controlled trial in a top-tier medical journal, which meets the evidence hierarchy almost every carrier publishes in its medical-policy bulletin.

A patient with documented coronary artery disease, prior myocardial infarction, or prior stroke who is also overweight or obese, and who has been denied Wegovy under the weight-loss exclusion, should appeal under the cardiovascular indication with the SELECT citation in the medical-evidence stack and the carrier's own pharmacy policy quoted back to it. The CMS March 2024 clarification on the cardiovascular indication should be cited in the regulatory hook section of the appeal.

The diabetes-or-obesity coding strategy

Semaglutide is marketed under two brand names. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management and for cardiovascular risk reduction. The molecule is the same. The labeled indications are different.

A patient with type 2 diabetes who is denied Wegovy for weight management often has a covered path through Ozempic for the diabetes indication. The clinical decision belongs to the physician, but the coverage logic is procedural. Carriers that exclude anti-obesity medications almost universally cover GLP-1 for type 2 diabetes, supported by the American Diabetes Association Standards of Care guidance. The same logic applies in reverse for patients without diabetes who are prescribed Ozempic off-label and denied: the procedural path is to switch the prescription to Wegovy under the on-label weight-management or cardiovascular indication, depending on the chart.

The diabetes-or-obesity coding question is not a workaround. It is a question of matching the prescription to the FDA-labeled indication that the chart actually supports. The carrier's pharmacy reviewer reads the prior-authorization request against the FDA label. The label that matches the chart is the label the appeal should anchor on.

The Medicare Part D step-therapy and prior-authorization landscape

Medicare Advantage and Part D plans have authority to apply step therapy and prior authorization under 42 CFR 422.136 and 42 CFR Part 423, Subpart M. The framework has tightened materially under the CMS prior-authorization interoperability rule finalized in early 2024 and codified at 42 CFR 422.119 et seq. (the rule known as CMS-0057-F). The rule sets standardized decision-timeframes, requires plans to provide specific reason codes for adverse determinations, and creates electronic prior-authorization data-exchange obligations that phase in through 2027.

For GLP-1 appeals, the CMS-0057-F framework matters because the standardized reason codes make it possible to identify the carrier's specific denial rationale and to anchor the appeal to the policy provision the carrier actually applied. A Part D denial that cites the statutory weight-loss exclusion is appealable under the cardiovascular indication where the chart supports it. A Medicare Advantage step-therapy denial that does not document the patient's prior trial-and-failure history is appealable under the same CFR section that authorizes step therapy. The Part D standard reconsideration window is 60 days; the expedited window is 72 hours where the patient or prescriber attests the standard timeframe could seriously jeopardize life, health, or ability to regain maximum function.

The parity and preventive-services angles

A growing share of GLP-1 prescriptions issued in 2025 and 2026 sit at the intersection of obesity coverage and eating-disorder treatment. The Mental Health Parity and Addiction Equity Act, codified at 29 CFR 2590.712, requires that financial requirements and treatment limitations applied to mental-health and substance-use-disorder benefits be no more restrictive than the predominant requirements applied to medical-surgical benefits. The 2024 final rule on MHPAEA strengthened the analytical framework for non-quantitative treatment limitations, which is the framework that governs prior-authorization and step-therapy rules. For a patient with a documented diagnosis of binge-eating disorder or another DSM-coded eating disorder prescribed a GLP-1 as part of a comprehensive treatment plan, the prior-authorization denial may be appealable not only on the medical-necessity track but also on the parity track. The path is narrow, the documentation requirement is high, and it is one of the more underused procedural levers in the 2026 GLP-1 appeal toolkit.

A small subset of GLP-1 appeals can also be framed under the preventive-services rule at 45 CFR 147.130, which requires non-grandfathered group health plans to cover, without cost-sharing, services with an "A" or "B" rating from the United States Preventive Services Task Force. The USPSTF has graded behavioral and pharmacologic interventions for adults with obesity, and the specific grades for GLP-1 pharmacotherapy continue to evolve. The framing does not apply to most commercial denials in the obesity lane. Where the USPSTF grade and the patient's clinical context align, it is the strongest procedural route available.

How carriers write GLP-1 denial letters

The letter you get almost always contains one of a small number of canonical phrases. Recognizing the phrase is the first step in routing the appeal to the right archetype. "Not medically necessary for the treatment of obesity under your pharmacy benefit" routes to archetype one, rebutted with FDA labeling for Wegovy or Zepbound plus the patient's BMI and comorbidity documentation. "Step therapy required, documentation of prior trial and failure of preferred agents is needed" routes to archetype two, rebutted with chart documentation of prior trials (dates, doses, duration, reason discontinued) and a step-therapy override request under the applicable state law or under 42 CFR 422.136 for Medicare Advantage. "Investigational or experimental for the indication requested" routes to archetype three, rebutted with the FDA approval date (Wegovy June 2021 for chronic weight management, March 2024 for cardiovascular risk reduction; Zepbound November 2023) and the carrier's own definition of "experimental," which almost always exempts FDA-approved uses. "Prescribing physician is not credentialed in the required specialty" routes to archetype four, rebutted with the carrier's network adequacy disclosure and state medical-practice scope law. The letter sometimes stacks these phrases. The appeal that wins reads each one and writes a paragraph against it, with the regulatory hook at the end.

Why a self-prepared GLP-1 appeal usually stalls

The four denial archetypes look distinct. They almost never arrive in isolation. A typical GLP-1 denial letter stacks not-medically-necessary language on top of a step-therapy gate on top of a BMI-threshold question, and the appeal that addresses one and not the others gets routed back as upheld. The library Apellica has catalogued (more than two hundred carrier-by-denial-type cells indexed at the pharmacy-policy-bulletin level) each carry their own preferred-agent list, BMI threshold, comorbidity inclusion list, and definition of "documented prior trial and failure."

The five regulatory regimes (ACA Marketplace, commercial fully insured, ERISA self-funded, Medicare Part D, state Medicaid) each carry their own deadline, appeal levels, and external-review pathway. Filing the right appeal in the wrong regime gets the case routed back without a substantive review. Procedural exhaustion missteps foreclose external review. Manufacturer-assistance programs require either an active prior authorization or a documented denial in the eligibility file, drafted correctly the first time. The carrier's pharmacy reviewer reads GLP-1 appeals all day. The patient is reading the policy for the first time, often while waiting for a refill that has not arrived.

What gets reversed

I am deliberately not giving a single headline reversal rate for GLP-1 appeals. The published payer-side data moves quarter to quarter, the denominators are not stable across carriers, and the mix of denial archetypes shifts as carriers update their formularies. The directional point holds across every payer-side dataset I have looked at. Step-therapy denials reverse at higher rates than not-medically-necessary denials when the chart documents prior trial and failure with the specificity the carrier requires. Experimental-or-investigational denials reverse at the highest rates because the FDA labeling defeats them on the face. Cardiovascular-indication appeals reverse at rates well above the median because the FDA labeling, the CMS clarification, and the SELECT trial all align. Pure not-medically-necessary denials under a plan that excludes anti-obesity medications outright are the hardest, because the carrier is enforcing a benefit-design exclusion, and the appeal has to find a covered indication the chart supports. The second look is materially more favorable to the patient than the first, in the GLP-1 lane as in every other denial class.

Where Apellica fits

Apellica prepares the evidence-based GLP-1 appeal letter. Disclosure: this is the firm I work for. The patient reviews and approves every word before submission and authorizes carrier communications under a HIPAA-compliant Assignment of Benefits. We are not a law firm. We are not a medical provider. We are not an insurance carrier. We are an independent administrative service that turns a denied claim into a properly documented appeal letter.

The model is $0 upfront and a flat fee on successful recovery. If the appeal does not reverse, the patient owes nothing for the preparation work. Coverage extends to all 50 states, every commercial and Medicare Advantage carrier, every Medicare Part D plan, every state Medicaid program, and every ERISA self-funded plan. A senior reviewer reads every case before it goes out. We do not work on cancer, oncology, or rare-disease cases; those belong with subspecialty advocates who do nothing else.

If you do not want to hire anyone, that is fine. Manufacturer assistance programs help if the carrier-side denial is documented correctly. NovoCare covers Wegovy and Ozempic for eligible commercially insured patients. The Lilly Zepbound Coverage Assistance Program covers Zepbound under a similar structure. The Patient Advocate Foundation Co-Pay Relief program administers diagnosis-based funds. NeedyMeds maintains a searchable database of manufacturer and nonprofit programs. The HealthWell Foundation runs disease-specific funds that periodically open for type 2 diabetes and cardiometabolic indications.

These programs change quickly. Apply to more than one in parallel, and document the carrier denial first; most manufacturer assistance programs require either an active prior authorization or a documented denial as part of the eligibility file.

If you are sitting on a GLP-1 denial right now

The next 48 hours after a denial arrives matter more than the next six months. Find the date in the upper right corner of the letter. Identify which of the five coverage regimes you sit in. Identify which of the four denial archetypes the letter contains, recognizing that a single letter can stack more than one. Calendar the appeal deadline: 180 days for ACA and ERISA, 60 days for Medicare Part D and Medicare Advantage. Request the carrier's pharmacy policy in writing and read it before drafting a word of the appeal. Pull the chart entries that document BMI, comorbidities, and prior trial-and-failure history with dates and doses. Identify whether the cardiovascular indication, the diabetes indication, the eating-disorder parity angle, or the preventive-services framing applies. Then build the appeal.

GLP-1 denials are appealable. The denial letter rarely says so, the pharmacy-benefit phone tree rarely surfaces the right pharmacy policy on the first call, and the cardiovascular and diabetes coding paths are rarely explained at the point of denial. The procedural overhead is the carrier's structural advantage, and it is the part of the process that is easiest to fix.

About the author

Mark Henderson is a senior reviewer at Apellica, an independent insurance appeal preparation service headquartered at One World Trade Center, New York, NY 10007. Apellica is not a law firm and does not provide legal advice. Coverage across all 50 states. Contact: press@apellica.com, +1 (888) 777-6120.

References

• 21 CFR Part 201. FDA prescription drug labeling requirements.
• 42 USC 1395w-102(e)(2)(A). Medicare Part D statutory exclusion of drugs used for weight loss.
• 42 CFR 422.119 et seq. CMS-0057-F prior-authorization interoperability rule.
• 42 CFR 422.136. Medicare Advantage step therapy.
• 42 CFR 422.582. Medicare Advantage standard reconsideration deadline.
• 42 CFR Part 423, Subpart M. Medicare Part D coverage determinations and appeals.
• 45 CFR 147.130. Coverage of preventive health services.
• 45 CFR 147.136. ACA internal claims and appeals and external review.
• 45 CFR 156.110. Essential Health Benefits.
• 29 CFR 2560.503-1. ERISA claims procedure.
• 29 CFR 2590.712. Mental Health Parity and Addiction Equity Act regulations.
• FDA approved labeling for Wegovy (semaglutide injection). accessdata.fda.gov.
• FDA approved labeling for Zepbound (tirzepatide injection). accessdata.fda.gov.
• FDA approved labeling for Ozempic (semaglutide injection). accessdata.fda.gov.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, December 2023.
• CMS, March 2024 clarification on Part D coverage of semaglutide for cardiovascular risk reduction. cms.gov.
• American Diabetes Association, Standards of Care in Diabetes, 2026.
• KFF, 2025 Employer Health Benefits Survey and GLP-1 coverage tracking. kff.org.
• Mercer, National Survey of Employer-Sponsored Health Plans, 2025.
• Commonwealth Fund, GLP-1 coverage tracking analyses, 2025-2026. commonwealthfund.org.
• NovoCare patient assistance program. novocare.com.
• Lilly Zepbound Coverage Assistance Program. zepbound.lilly.com.
• Patient Advocate Foundation Co-Pay Relief. patientadvocate.org/co-pay-relief.
• NeedyMeds. needymeds.org.
• HealthWell Foundation. healthwellfoundation.org.
• United States Preventive Services Task Force. uspreventiveservicestaskforce.org.